Previous Page  12 / 25 Next Page
Information
Show Menu
Previous Page 12 / 25 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 52

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

Introduction:

Portal hypertension is one of themain cause of post-

transplant graft dysfunction in living donor liver transplant (LDLT).

Modification of the portal flow has been suggested to decrease

portal pressure. One possible, splenic artery ligation (SAL), has

been performed in recipients with elevated portal vein flow. Even

though the short term results with SAL in LDLT are excellent, the

long term outcomes and postoperative complications have been

yet to be determined.

Methods:

From August 2010 to August 2016, 87 LDLT were

performed at the STI (Starzl Transplant Institute) of the University

of Pittsburgh. Two patients had previous splenectomy and were

excluded. Of 85 patients, 42 had SAL preformed. We compared

results in patients with SAL or without SAL retrospectively after

an IRB (institutional review board) approved by STI. LDLT was

performed using either the right or left lobe.

Results:

The study showed that SAL significantly decreased

mean portal pressure (19.2±1.7 pre-SAL vs 15±1.8 post-SAL,

p=0.0014). Of the 42 patients that had SAL, 7 (16.6%) developed

splenic infarction as noted on routine CT imaging, but only one

developed splenic abscess. No statistically difference was found

in postoperative infection, postoperative wound complication and

surgical complication rates between patients with/without SAL

(p=0.50,p=0.166, p=0.237). Although the mortality rate was lower

in patients with SAL, it was not statistically significant (11% vs

28%, p=0.059).

Conclusions:

Overall, SAL is safe and effective to decrease portal

pressure without increasing risk of morbidity and mortality in

recipient undergoing LDLT.

drygunay@gmail.com

The safety and efficacy of splenic artery ligation in living

donor liver transplant recipients

Yusuf Gunay

1

and

Abhinav Humar

2

1

Zonguldak Bulent Ecevit University, Turkey

2

Thomas E Starzl Transplant Institute – UPMC, USA

J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-006